Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 6/20 | 0.72 |
| ▸ | RAB9A | P51151 | 5/20 | 0.72 |
| ▸ | HPGD | P15428 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 5/20 | 0.69 |
| ▸ | CDK5 | Q00535 | 5/20 | 0.69 |
| ▸ | CDK5R1 | Q15078 | 5/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.69 |
| ▸ | MEN1 | O00255 | 3/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.69 |
| ▸ | CCNA2 | P20248 | 8/20 | 0.68 |
| ▸ | CDK2 | P24941 | 8/20 | 0.68 |
| ▸ | GSK3B | P49841 | 2/20 | 0.68 |
| ▸ | GSK3A | P49840 | 1/20 | 0.68 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.56 |
| ▸ | DHODH | Q02127 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7759391 | 0.87 | NPC1 (0.70) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL1250529 | 0.85 | NPC1 (0.72) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL7753436 | 0.85 | CCNA2 (0.76) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL7757552 | 0.85 | CCNA2 (0.76) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL4479010 | 0.84 | GSK3A (0.69) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL4479206 | 0.83 | CCNA2 (0.77) | CDK5CDK5R1CCNA2CDK2GSK3B | |
| SCHEMBL1250849 | 0.82 | CDK5 (1.00) | NPC1RAB9AMAPTCDK5CDK5R1 | |
| SCHEMBL7753445 | 0.82 | MAPT (0.61) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL4558262 | 0.82 | MAPT (0.67) | NPC1RAB9AHPGDMAPTCDK5 | |
| SCHEMBL7756942 | 0.82 | MAPT (1.00) | NPC1RAB9AHPGDMAPTCDK5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| US-7605154-B2 | ATP-protein kinase inhibitors; cytomegalovirus; contraceptive agents; cancer; N7-(3-ethynyl-phenyl)-N2-(4-piperidin-1-ylmethyl-phenyl)-thiazolo[4,5-d]pyrimidine-2,7-diamine | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-10-20 | — | — | US | disclosed |
| EP-1912639-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-04-23 | — | — | EP | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-08-09 | — | — | US | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| WO-2007019191-A2 | THIAZOLOPYRIMIDINE KINASE INHIBITORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-02-15 | — | — | WO | disclosed |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | NOVO NORDISK A/S (DK) | 2001-11-08 | — | — | US | disclosed |
| WO-2001056567-A1 | 2,4-DIAMINOTHIAZOLE DERIVATIVES AND THEIR USE AS GLYCOGEN SYNTHASE KINASE-3 (GSK-3) INHIBITORS | NOVO NORDISK A/S (DK) | 2001-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185139-A1 | Thiazolopyrimidine kinase inhibitors | ABL1, MAP3K19, PI4KB | NPC1 2373/4885RAB9A 3220/4885HPGD 2721/4885 |
| US-20010039275-A1 | Use of 2,4-diaminothiazole derivatives | GSK3A, GSK3B, GSKIP | NPC1 797/4885RAB9A 4452/4885HPGD 1738/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.